Laurus Labs Ltd has recently received a final approval from United States Food and Drug Administration (US FDA) for Hydroxychloroquine Tablets 200 mg which is used for treatment of certain type of Malaria. This medication is also used, usually with other medications, to treat certain auto-immune diseases (lupus, rheumatoid arthritis) when other medications have not worked or cannot be used. Hydroxychloroquine Tabs 200 Mg is therapeutically equivalent to Plaquenil Tablets 200mg of Concordia Pharmaceuticals, Inc.
In another development, the Company also received a tentative approval for an ANDA for Abacavir, Dolutegravir, and Lamivudine, Tablets 600 mg/50 mg/300 mg from USFDA.
The products will be commercialized from Laurus' manufacturing site located at Atchutapuram, Visakhapatnam.
Shares of Laurus Labs Ltd was last trading in BSE at Rs.350 as compared to the previous close of Rs. 351.5. The total number of shares traded during the day was 1060525 in over 569 trades.
The stock hit an intraday high of Rs. 357.95 and intraday low of 348.7. The net turnover during the day was Rs. 371227677.